疾病
亨廷顿病
神经炎症
亨廷顿蛋白
医学
临床试验
神经科学
治疗方法
生物信息学
生物
病理
作者
Nicholas S. Caron,E. Ray Dorsey,Michael R. Hayden
摘要
The 25 years since the identification of the gene responsible for Huntington disease (HD) have stood witness to profound discoveries about the nature of the disease and its pathogenesis. Despite this progress, however, the development of disease-modifying therapies has thus far been slow. Preclinical validation of the therapeutic potential of disrupted pathways in HD has led to the advancement of pharmacological agents, both novel and repurposed, for clinical evaluation. The most promising therapeutic approaches include huntingtin (HTT) lowering and modification as well as modulation of neuroinflammation and synaptic transmission. With clinical trials for many of these approaches imminent or currently ongoing, the coming years are promising not only for HD but also for more prevalent neurodegenerative disorders, such as Alzheimer and Parkinson disease, in which many of these pathways have been similarly implicated.
科研通智能强力驱动
Strongly Powered by AbleSci AI